Happening tomorrow! Join CEO Pascal Touchon and CSO Cokey Nguyen for a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The presentation will be webcast live at: https://bit.ly/3VBZCdY, with a replay available shortly thereafter.
Atara Biotherapeutics
Biotechnology Research
Thousand Oaks, CA 36,443 followers
Pioneering off-the-shelf, allogeneic T-cell immunotherapies
About us
Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.
- Website
-
http://www.atarabio.com
External link for Atara Biotherapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Thousand Oaks, CA
- Type
- Public Company
- Founded
- 2012
- Specialties
- biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis
Locations
-
Primary
Get directions
2380 Conejo Spectrum St
Suite 200
Thousand Oaks, CA 91320, US
-
Get directions
12635 East Montview Boulevard
Suite 280
Aurora, CO 80045, US
Employees at Atara Biotherapeutics
Updates
-
CSO Cokey Nguyen will be joining a panel with fellow cell therapy experts this Thursday at #BIO2024 in San Diego on June 6. Join us to learn about the latest developments and future trends in #allogeneic cell therapies, which are poised to usher in a new wave of innovation.
-
-
We are pleased to announce that Atara will be presenting new #SLE and #MS preclinical data today for our investigational CD19 #allogeneic #CART therapy, ATA3219, at the International Society for Cell & Gene Therapy 2024 Annual Meeting in Vancouver, Canada. Read all the details here: https://bit.ly/3yzWrKO
-
Today Atara announced that it submitted a Biologics License Application (BLA) to the U.S. FDA for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus (#EBV) positive post-transplant lymphoproliferative disease (#PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. This represents the first-ever #allogeneic #Tcell therapy BLA submission to the FDA, and if approved, tab-cel would be the first approved therapy in the U.S. for EBV+ PTLD. Read more about this significant milestone for Atara: https://bit.ly/4dL7elE
-
-
Check out CEO Pascal Touchon featured in this report highlighting the latest developments and potential of #allogeneic #Tcell products in oncology and autoimmune diseases. https://lnkd.in/gHPfc4P7
HOT OF THE PRESS: The New Era of Life Sciences 2024 This report captures a historical moment for life sciences. What were dreams or vague projections until recently are now solidifying realities. Highly personalized oncology therapies, the possibility of early cancer detection via a simple blood draw, AI’s optimization of drug discovery, unseen breakthroughs in the formerly stagnating fields of neurology or dermatology - inspiring illustrations of each of these, and more, can be found in this piece, the result of more than 100 conversations with industry leaders. Dive deep into 'The New Era of Life Sciences' report, a comprehensive exploration of the advancements shaping healthcare and beyond. READ FULL REPORT: https://lnkd.in/diZsNp3i
-
-
Hear from our CSO, Cokey Nguyen, on how Atara is leveraging its #EBV T cells for our promising #allogeneic #CART platform in oncology and autoimmune diseases. Read the entire article starting on page 44 here: https://lnkd.in/dv3Bi45P
-
-
Today we announced our first quarter 2024 financial results and operational progress. The latest news is available here: https://bit.ly/4adw4rd #celltherapy #allogeneic #CART $ATRA
-
-
Tune in today at 11:30am PT as CEO Pascal Touchon presents a company overview at the Aegis Capital Corp. Virtual Conference. Register here: https://bit.ly/3JQGOkv
-
-
ICYMI, CSO Cokey Nguyen joined a Cell & Gene Live session to discuss the current and future trends of #allogeneic #Tcell therapies for oncology, and the latest manufacturing strategies and approaches to help bring these off-the-shelf treatments to patients.
Don't miss tomorrow's Cell & Gene Live Event! Atara Biotherapeutics Dr. Cokey Nguyen and Poseida Therapeutics, Inc.'s Loren Wagner join Cell & Gene Live’s Erin Harris for an interactive discussion on the potential trends driving the future of #allogeneic #therapies for #oncology. Supported by Thermo Fisher Scientific. Register here: https://lnkd.in/ewgPzkdq
-
Join us Monday at the Festival of Biologics in San Diego where Christina Pham, Director of Preclinical Research, will be presenting on how our #allogeneic #EBV #CART programs are helping to usher in a new wave of innovation. Hope to see you there!
-